Trends in Extracorporeal Membrane Oxygenation Application and Outcomes in Korea.
Eun Jin JangSun-Young JungHyun Joo LeeMyo-Song KimKwon Joong NaSamina ParkIn Kyu ParkChang Hyun KangYoung Tae KimPublished in: ASAIO journal (American Society for Artificial Internal Organs : 1992) (2021)
The use of extracorporeal membrane oxygenation (ECMO) is increasing despite the limited evidence in survival benefit. This study aimed to analyze the changes of in-hospital mortality, medical costs, and other outcomes in ECMO therapy. We used 2004-2017 data from a nationwide healthcare administrative claims database in Korea. Overall, 14,775 ECMO procedures were performed in 14,689 patients at 112 hospitals. We found a 170-fold and a 334-fold increase in the number of ECMO procedures and related costs, respectively. For indications, the performance of ECMO for heart or lung transplantation and respiratory failure increased, whereas that for cardiovascular surgery decreased. The duration of ECMO increased from a median of 3 days (IQR, 2-5 days) in 2004 to 4 days (IQR, 2-9 days) in 2017. The overall in-hospital mortality rate was 68.6%, and this improved over time, especially for lung transplantation and respiratory failure patients. Bleeding-related complications and the transfusion amount also decreased. Hospitals with higher case volume showed better survival outcomes. The median cost per procedure and per day was 26,538 USD (IQR, 14,646-47,862 USD) and 1,560 USD (IQR, 903-2,929 USD), respectively, and increased with time. A trend toward greater resource use and better outcomes requires additional cost-effective analysis based on indications.
Keyphrases
- extracorporeal membrane oxygenation
- respiratory failure
- acute respiratory distress syndrome
- healthcare
- minimally invasive
- mechanical ventilation
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- atrial fibrillation
- cardiac surgery
- type diabetes
- stem cells
- heart failure
- adipose tissue
- bone marrow
- risk factors
- health insurance
- insulin resistance
- coronary artery disease
- acute kidney injury
- mesenchymal stem cells
- skeletal muscle
- patient reported
- smoking cessation
- cell therapy
- replacement therapy
- drug induced
- sickle cell disease